On the limitation of 6-tioguaninenucleotide monitoring during tioguanine treatment

Alimentary Pharmacology and Therapeutics

Volumn 22, Issue 5, 2005, Pages 447-451

  De Boer, N K H ^a   De Graaf, P ^a   Wilhelm, A J ^a   Mulder, C J J ^a   Van Bodegraven, A A ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

6 TIOGUANINENUCLEOTIDE; AZATHIOPRINE; DRUG METABOLITE; HEMOGLOBIN; MERCAPTOPURINE; TIOGUANINE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; AUTOIMMUNE DISEASE; BONE MARROW DEPRESSION; BONE MARROW TOXICITY; CELIAC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DOSE RESPONSE; DRUG EFFECT; DRUG ERYTHROCYTE LEVEL; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG MONITORING; FEMALE; GASTROINTESTINAL DISEASE; HEMOGLOBIN DETERMINATION; HEPATITIS; HUMAN; LEUKOCYTE COUNT; LIVER TOXICITY; MALAISE; MALE; MYALGIA; PHARMACOGENETICS; PRIORITY JOURNAL; THROMBOCYTE COUNT; ULCERATIVE COLITIS;

ADULT; ANTIMETABOLITES, ANTINEOPLASTIC; BONE MARROW DISEASES; CELIAC DISEASE; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; HEPATITIS, AUTOIMMUNE; HUMANS; MALE; THIOGUANINE;

EID: 24344467121     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2005.02581.x     Document Type: Article

References (18)

1. Al Hadithy AF, de Boer NK, Derijks LJ, Escher JC, Mulder CJ, Brouwers JR. Thiopurines in inflammatory bowel disease: pharmacogenetics, therapeutic drug monitoring and clinical recommendations. Dig Liver Dis 2005; 37: 282-97.
2. De Jong DJ, Derijks LJ, Naber AH, Hooymans PM, Mulder CJ. Safety of thiopurines in the treatment of inflammatory bowel disease. Scand J Gastroenterol Suppl 2003; 239: 69-72.
3. De Jong D, Mulder CJ, van Sorge AA. Why measure thiopurine methyltransferase activity? Direct administration of 6-thioguanine might be the alternative for 6-mercaptopurine or azathioprine. Gut 2001; 49: 874.
4. Dubinsky MC, Hassard PV, Seidman EG, et al. An open-label pilot study using thioguanine as a therapeutic alternative in Crohn's disease patients resistant to 6-mercaptopurine therapy. Inflamm Bowel Dis 2001; 7: 181-9.
5. De Boer NK, van Nieuwkerk CM, Aparicio Pages MN, de Boer SY, Derijks LJ, Mulder CJ. Promising treatment of autoimmune hepatitis with 6-thioguanine after adverse events on azathioprine. Eur J Gastroenterol Hepatol 2005; 17: 457-61.
6. Dubinsky MC, Vasiliauskas EA, Singh H, et al. 6-thioguanine can cause serious liver injury in inflammatory bowel disease patients. Gastroenterology 2003; 125: 298-303.
7. Connell WR, Kamm MA, Ritchie JK, Lennard-Jones JE. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 1993; 34: 1081-5.
8. Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000; 118: 705-13.
9. Schutz E, Gummert J, Mohr FW, Armstrong VW, Oellerich M. Azathioprine myelotoxicity related to elevated 6-thioguanine nucleotides in heart transplantation. Transplant Proc 1995; 27: 1298-300.
10. Herrlinger KR, Fellermann K, Fischer C, et al. Thioguanine-nucleotides do not predict efficacy of tioguanine in Crohn's disease. Aliment Pharmacol Ther 2004; 19: 1269-76.
11. Dubinsky MC, Feldman EJ, Abreu MT, Targan SR, Vasiliauskas EA. Thioguanine: a potential alternate thiopurine for IBD patients allergic to 6-mercaptopurine or azathioprine. Am J Gastroenterol 2003; 98: 1058-63.
12. Derijks LJ, de Jong DJ, Gilissen LP, et al. 6-Thioguanine seems promising in azathioprine- or 6-mercaptopurine-intolerant inflammatory bowel disease patients: a short-term safety assessment. Eur J Gastroenterol Hepatol 2003; 15: 63-7.
13. Derijks LJ, Gilissen LP, Engels LG, et al. Pharmacokinetics of 6-mercaptopurine in patients with inflammatory bowel disease: implications for therapy. Ther Drug Monit 2004; 26: 311-8.
14. Lowry PW, Franklin CL, Weaver AL, et al. Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease. Gut 2001; 49: 665-70.
15. Bonaz B, Boitard J, Marteau P, et al. Tioguanine in patients with Crohn's disease intolerant or resistant to azathioprine/mercaptopurine. Aliment Pharmacol Ther 2003; 18: 401-8.
16. Herrlinger KR, Deibert P, Schwab M, et al. Remission maintenance by tioguanine in chronic active Crohn's disease. Aliment Pharmacol Ther 2003; 17: 1459-64.
17. Lancaster DL, Patel N, Lennard L, Lilleyman JS. Leucocyte versus erythrocyte thioguanine nucleotide concentrations in children taking thiopurines for acute lymphoblastic leukaemia. Cancer Chemother Pharmacol 2002; 50: 33-6.
18. Tiede I, Fritz G, Strand S, et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest 2003; 111: 1133-45.